What are the indications, dosing regimens, and monitoring requirements for nebulized epinephrine (adrenaline) in children (6 months–6 years and older) and adults with acute upper airway obstruction (viral croup), bronchiolitis, severe asthma, or anaphylaxis?

Nebulized Epinephrine Use

Nebulized epinephrine is primarily indicated for acute upper airway obstruction from croup in children, where it provides rapid but short-lived symptom relief (1-2 hours), and should not be used in outpatient or near-discharge settings due to rebound risk. 1

Primary Indication: Croup (Viral Laryngotracheobronchitis)

Dosing for Croup

• Standard dose: 0.5 ml/kg of 1:1000 solution (maximum 5 mg) 1
• Low-dose alternative: 0.1 mg/kg has been shown non-inferior to 0.5 mg/kg for moderate to severe croup 2
• Racemic epinephrine alternative: 0.5 mL of 2.25% solution diluted in 2.5 mL saline 3
• Age range: Children 6 months to 6 years 3

Critical Safety Considerations for Croup

• Effect duration is only 1-2 hours, creating significant rebound risk 1
• Must NOT be used in children about to be discharged or on an outpatient basis 1
• Primary use: To avoid intubation, stabilize children prior to ICU transfer, or manage post-intubation stridor 1
• Children requiring two epinephrine treatments should be hospitalized 3
• Always administer with dexamethasone 0.6 mg/kg 2, 3

Monitoring After Administration

• Croup scores should be measured at baseline, then at 30,60,90, and 120 minutes post-treatment 2
• Heart rate increases of 7-21 beats per minute may occur up to 60 minutes after treatment 4
• Pallor may occur in up to 47.6% of patients within 30 minutes 4
• Blood pressure typically remains stable with doses of 3-5 ml 4

Bronchiolitis: Limited Role

Nebulized epinephrine is NOT routinely recommended for bronchiolitis in most settings. 5, 6

Evidence Summary

• A 2003 randomized controlled trial showed nebulized epinephrine (2 ml of 1:1000) did not significantly reduce hospital admissions compared to saline (50% vs 38%, not statistically significant) 5
• No difference in respiratory rate, oxygen saturation, heart rate, or respiratory distress scores at 30,60, or 120 minutes 5
• Recent 2025 Australasian guidelines suggest combined glucocorticoids/inhaled epinephrine may have a role specifically in severe bronchiolitis requiring ICU-level care 7
• Meta-analyses show potential therapeutic effects in outpatient settings, but evidence quality remains low to moderate 6

When to Consider in Bronchiolitis

• High-risk infants or those with severe disease may be considered for therapeutic trial 6
• ICU-level severe bronchiolitis in combination with glucocorticoids 7
• Not for routine use in emergency departments or outpatient settings 5, 6

Severe Asthma: NOT Indicated

Nebulized epinephrine has no established role in acute severe asthma management. 1

The British Thoracic Society guidelines for acute severe asthma specify:

• Nebulized bronchodilators: Salbutamol 5 mg or 0.15 mg/kg, or Terbutaline 10 mg or 0.3 mg/kg 1
• Add ipratropium 250 mcg six hourly for severe cases 1
• Oxygen should be the driving gas whenever possible 1
• If inhaled route unavailable, subcutaneous terbutaline 2.5 mg may be used 1
• Epinephrine is not mentioned as a treatment option in asthma guidelines 1

Adult Upper Airway Obstruction: Case Reports Only

Limited evidence exists for nebulized epinephrine in adults with upper airway obstruction. 8

• Case series reports successful use of 1 mg in 5 ml normal saline, repeated as necessary 8
• Used for various etiologies of upper airway obstruction with immediate benefits and few cardiovascular sequelae 8
• This remains off-label use based on case reports, not controlled trials 8

Anaphylaxis: Intramuscular Route is Standard

Nebulized epinephrine has NO role in anaphylaxis treatment. 9

• Intramuscular epinephrine remains the first-line treatment for anaphylaxis 9
• Prompt use of epinephrine autoinjector is critical 9
• If epinephrine is used promptly with complete and durable response, immediate 911 activation may not be required 9

FDA-Approved Dosing for Hand-Held Nebulizers

For over-the-counter racemic epinephrine products 10:

• Concentration: 1% epinephrine solution (Racepinephrine 11.25 mg per 0.5 ml) 10
• Adults and children ≥4 years: 1-3 inhalations not more often than every 3 hours 10
• Maximum: 12 inhalations in 24 hours 10
• Children <4 years: Ask a doctor 10
• Use requires adult supervision for children 10

Delivery Efficiency Considerations

Delivery method significantly impacts drug delivery. 11

• Facemask delivers only 2-10% of nebulized dose 11
• Laryngeal mask airway (LMA) delivers 8-15% 11
• Endotracheal tube (ETT) delivers 12-32%, approximately twice that of LMA 11
• ETT delivers approximately 4 times more than facemask in infants and young children 11

Key Clinical Pitfalls

1. Never discharge a child immediately after nebulized epinephrine for croup - the 1-2 hour effect duration creates dangerous rebound risk 1

2. Do not confuse nebulized epinephrine with intramuscular epinephrine - they have completely different indications and cannot be substituted 9

3. Avoid routine use in bronchiolitis - evidence does not support benefit in most cases 5

4. Do not use for asthma - established bronchodilators (salbutamol, terbutaline) are the evidence-based treatments 1

5. Monitor for cardiovascular effects - though generally safe, tachycardia and pallor can occur 4